Combined analysis of r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' plasma.

2.50
Hdl Handle:
http://hdl.handle.net/10146/42495
Title:
Combined analysis of r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' plasma.
Authors:
Carmella, Steven G.; Yoder, Andrea; Hecht, Stephen S.
Abstract:
Polycyclic aromatic hydrocarbons (PAH) and tobacco-specific nitrosamines, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), are widely accepted to be two important types of lung carcinogens in cigarette smoke. In this study, we have developed a method to estimate individual uptake of these compounds by quantifying r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene (PheT) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in 1 mL of smokers' plasma. PheT and NNAL are biomarkers of PAH and NNK uptake, respectively. [D10]PheT and [pyridine-D4]NNAL were added to plasma as internal standards. The plasma was treated with beta-glucuronidase to release any conjugated PheT and NNAL. The analytes were enriched by solid-phase extraction on a mixed mode cation exchange cartridge and the PheT fraction was further purified by high-performance liquid chromatography. The appropriate fractions were analyzed by gas chromatography-negative ion chemical ionization-mass spectrometry for PheT and liquid chromatography-electrospray ionization-mass spectrometry for NNAL. The method was sensitive (limits of quantitation: PheT, 13 fmol/mL; NNAL, 3 fmol/mL), accurate, and precise. Levels of PheT and NNAL in plasma from 16 smokers averaged 95 +/- 71 and 36 +/- 21 fmol/mL, respectively, which are approximately 1% to 2% of the amounts found in urine. This method should be useful in molecular epidemiology studies of carcinogen uptake and lung cancer in smokers.
Citation:
Cancer Epidemiol. Biomarkers Prev. 2006, 15 (8):1490-1494
Journal:
Cancer Epidemiology, Biomarkers & Prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Issue Date:
Aug-2006
URI:
http://hdl.handle.net/10146/42495
DOI:
10.1158/1055-9965.EPI-06-0199
PubMed ID:
16896038
Additional Links:
http://cebp.aacrjournals.org/cgi/content/full/15/8/1490
Type:
Article
Language:
en
Description:
Biomarkers of exposure & effect: method development & validationBiomarker: r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene (PheT) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) Exposure/effect represented:exposure to PAH and NNK Tissue: plasma Analytical technicque: GC-MS & HPLC-EI-MS/MS <BR>Sensitivity (LOD): PheT: 13 fmol/ml; NNAL: 3 fmol/ml Accuracy: Spiking plasma which contained 47 fmol/mL PheT, with 50, 100, 150, and 200 fmol/mL PheT, followed by analysis, led to a linear dose-response with r = 0.97 and y intercept = 54 fmol/mL. PheT recovery was 26+11%. Spiking plasma which contained 30 fmol/ml NNAL with 25, 50, 75, and 100 fmol/mL NNAL, followed by analysis, led to a linear dose-response with r = 0.99 and y intercept = 24 fmol/mL. NNAL recovery was 43+21%. Intraday precision: PheT: SD 6.5%; NNAL: SD 7.7% Interday precision: PheT: SD 13.7%; NNAL: SD 11.7%
ISSN:
1055-9965
Sponsors:
Grant support: National Cancer Institute grants CA-92025 and CA-77598 and NIH grant DA-13333. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Appears in Collections:
Articles with annotation

Full metadata record

DC FieldValue Language
dc.contributor.authorCarmella, Steven G.-
dc.contributor.authorYoder, Andrea-
dc.contributor.authorHecht, Stephen S.-
dc.date.accessioned2008-12-18T11:54:41Z-
dc.date.available2008-12-18T11:54:41Z-
dc.date.issued2006-08-
dc.identifier.citationCancer Epidemiol. Biomarkers Prev. 2006, 15 (8):1490-1494en
dc.identifier.issn1055-9965-
dc.identifier.pmid16896038-
dc.identifier.doi10.1158/1055-9965.EPI-06-0199-
dc.identifier.urihttp://hdl.handle.net/10146/42495-
dc.descriptionBiomarkers of exposure & effect: method development & validationBiomarker: r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene (PheT) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) Exposure/effect represented:exposure to PAH and NNK Tissue: plasma Analytical technicque: GC-MS & HPLC-EI-MS/MS <BR>Sensitivity (LOD): PheT: 13 fmol/ml; NNAL: 3 fmol/ml Accuracy: Spiking plasma which contained 47 fmol/mL PheT, with 50, 100, 150, and 200 fmol/mL PheT, followed by analysis, led to a linear dose-response with r = 0.97 and y intercept = 54 fmol/mL. PheT recovery was 26+11%. Spiking plasma which contained 30 fmol/ml NNAL with 25, 50, 75, and 100 fmol/mL NNAL, followed by analysis, led to a linear dose-response with r = 0.99 and y intercept = 24 fmol/mL. NNAL recovery was 43+21%. Intraday precision: PheT: SD 6.5%; NNAL: SD 7.7% Interday precision: PheT: SD 13.7%; NNAL: SD 11.7%en
dc.description.abstractPolycyclic aromatic hydrocarbons (PAH) and tobacco-specific nitrosamines, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), are widely accepted to be two important types of lung carcinogens in cigarette smoke. In this study, we have developed a method to estimate individual uptake of these compounds by quantifying r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene (PheT) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in 1 mL of smokers' plasma. PheT and NNAL are biomarkers of PAH and NNK uptake, respectively. [D10]PheT and [pyridine-D4]NNAL were added to plasma as internal standards. The plasma was treated with beta-glucuronidase to release any conjugated PheT and NNAL. The analytes were enriched by solid-phase extraction on a mixed mode cation exchange cartridge and the PheT fraction was further purified by high-performance liquid chromatography. The appropriate fractions were analyzed by gas chromatography-negative ion chemical ionization-mass spectrometry for PheT and liquid chromatography-electrospray ionization-mass spectrometry for NNAL. The method was sensitive (limits of quantitation: PheT, 13 fmol/mL; NNAL, 3 fmol/mL), accurate, and precise. Levels of PheT and NNAL in plasma from 16 smokers averaged 95 +/- 71 and 36 +/- 21 fmol/mL, respectively, which are approximately 1% to 2% of the amounts found in urine. This method should be useful in molecular epidemiology studies of carcinogen uptake and lung cancer in smokers.en
dc.description.sponsorshipGrant support: National Cancer Institute grants CA-92025 and CA-77598 and NIH grant DA-13333. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.en
dc.language.isoenen
dc.relation.urlhttp://cebp.aacrjournals.org/cgi/content/full/15/8/1490en
dc.subject.meshBiological Markers-
dc.subject.meshChromatography, High Pressure Liquid-
dc.subject.meshChromatography, Liquid-
dc.subject.meshGas Chromatography-Mass Spectrometry-
dc.subject.meshGlucuronidase-
dc.subject.meshHumans-
dc.subject.meshNitrosamines-
dc.subject.meshPhenanthrenes-
dc.subject.meshPyridines-
dc.subject.meshSmoking-
dc.titleCombined analysis of r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' plasma.en
dc.typeArticleen
dc.identifier.journalCancer Epidemiology, Biomarkers & Prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncologyen

Related articles on PubMed

All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.